Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|March 16, 2021

Risky Business: The Higher Risk of Nonsuicidal Self Injury in Bisexual Individuals

Author(s)Brendan J. Dunlop

Bisexual individuals are at 4.5 to 6 higher risk of self harming than heterosexual individuals, according to this online study.

Brendan Dunlop talks about the self-harm risks and nuanced needs of bisexual individuals. For updates on the study, follow them on Twitter here.

Brendan J. Dunlop is a clinical psychologist in training at the University of Manchester, UK, and co-investigator on the Self-Injury in Young Bisexual People - a Longitudinal Investigation (SIBL) study.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

August theme: suicide

Presenting Our August 2026 Theme: Suicide

August 5th 2026

sex

Podcast: Exploring the Intersection of Sex and Psychiatry With Brittany Albright, MD, MPH

ByFrank A. Clark, MD,Brittany Albright, MD, MPH

July 29th 2026

tech landscape

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

BySarah Cheema, MD,Andrew Canto, MD,Nicolas Badre, MD

July 21st 2026

1 expert is featured in this series.

Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy

ByDavid Walling, PhD

July 8th 2026

1 expert is featured in this series.

Managing Tolerability and Setting Patients Up for Success with Cobenfy

ByDavid Walling, PhD

July 1st 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?

Insanity Trials and The Court of Popular Opinion

Novel Serotonergic Agonist, HLP003, Targets the Adjunctive MDD Treatment Gap

Modified Titration Dosing Reduces ARIA-E Risk With Donanemab, A Discussion With John Sims, MD

Biomarker Testing for Alzheimer Disease: Inside the Latest P-Tau217 Data